Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update
13 nov. 2024 06h30 HE
|
Liquidia Corporation
Liquidia Corporation (LQDA) today reported financial results for the third quarter ended September 30, 2024.
Liquidia to Present at the Stifel 2024 Healthcare Conference
12 nov. 2024 08h00 HE
|
Liquidia Corporation
Liquidia Corporation (LQDA) to present at the Stifel 2024 Healthcare Conference in New York City on Tuesday, November 19, 2024, from 3:00 – 3:30 p.m. ET.
Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 13, 2024
06 nov. 2024 08h00 HE
|
Liquidia Corporation
Liquidia Corporation (LQDA) to report its third quarter 2024 financial results on November 13, 2024, via webcast at 8:30 a.m. ET
Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 11, 2024
04 nov. 2024 08h00 HE
|
Liquidia Corporation
Liquidia Corporation (NASDAQ: LQDA), to report its third quarter 2024 financial results via webcast at 8:30 a.m. ET on Friday, November 8, 2024.
United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent
07 oct. 2024 10h00 HE
|
Liquidia Corporation
U.S. Supreme Court denied United Therapeutics’ petition to appeal rulings that found all claims of U.S. Patent No. 10,716,793 (‘793 Patent) were invalidDecisions that Liquidia does not infringe any...
Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)
02 oct. 2024 06h00 HE
|
Liquidia Corporation
Liquidia and Pharmosa announced they have amended the current exclusive licensing agreement for the development and commercialization of L606.
Liquidia Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting
30 sept. 2024 08h00 HE
|
Liquidia Corporation
Liquidia will present a poster and host a medical theater at the CHEST 2024 annual meeting hosted by the American College of Chest Physicians this October.
Court Finds United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million
16 sept. 2024 09h41 HE
|
Liquidia Corporation
MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia), a biopharmaceutical company developing innovative therapies for patients with rare...
Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement
11 sept. 2024 08h26 HE
|
Liquidia Corporation
Liquidia Corporation announces raise of $67.5M.
Liquidia to Present at Upcoming Investor Conferences
28 août 2024 08h00 HE
|
Liquidia Corporation
Liquidia Corporation (LQDA) announced today that the company will present at two investor conferences this September.